All In Biotech

Drug Trial Radar · NCT05672121

Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

A Phase I/II, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Feb 6, 2023

Primary completion

Dec 28, 2026

Study completion Dec 28, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • KH631Drug

    KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: 24 weeks
  2. Change in best corrected visual acuityTime frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.